ICON plc. Shares trade on Nasdaq amid steady business backdrop.

ICON plc stock remains tied to clinical-development demand and the company's global contract research model. The Irish group is listed on Nasdaq and serves pharmaceutical and biotech clients worldwide.

By Julia Smith, Sector & Peers desk. Reviewed on July 3, 2026 at 6:37 p.m. ET.

ICON plc (IE0005711209) is a global contract research organization listed on Nasdaq, with work centered on clinical development services for drug makers and biotech companies. The stock's appeal often tracks the pace of trial activity, customer spending, and the broader outsourcing trend in drug development.

Clinical trial services

ICON's core business covers study design, patient recruitment support, data management, and other services that help sponsors run clinical programs. That mix gives the company exposure to recurring demand from large pharmaceutical clients as well as smaller developers that need external trial expertise.

Market position

For US readers, the Nasdaq listing matters because it places the shares within a familiar market frame alongside other healthcare services names. The company also operates in a sector where investor attention often shifts with pipeline news, regulatory milestones, and R&D budgets.

Representative service line

One representative part of the business is full-service clinical development, where ICON supports sponsors from early-stage planning through study execution and reporting. That model makes the company a middle layer in drug development rather than a drug maker itself.

Stock and valuation

As of July 3, 2026, ICON plc shares trade on Nasdaq in US dollars, but no live price quote is included here. The company remains a healthcare services name whose next move will depend more on execution and industry demand than on product launches.

Fact box

• Company: ICON plc
• ISIN: IE0005711209
• Ticker: ICLR
• Exchange: Nasdaq
• Sector / Industry: Healthcare / Life Sciences Tools & Services
• Index membership: not verified in this call
• Next earnings date: not yet officially scheduled

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.